To operate successfully within the exosome marketplace, it is vital to assess novel opportunities for product development. Currently, there are five market segments that compose the market for stem cell exosomes. These market segments include: Exosome therapeutics, diagnostic tools, research tools, cosmeceuticals, and manufacturing technologies. [Read more…]
BioInformant Releases “Market for Stem Cell Exosomes”
Washington DC (Newswire) — BioInformant has launched the “Market for Stem Cell Exosomes – Products, Services, & Technologies,” a global strategic report targeting the growing demand for exosome therapeutics, diagnostics, and research tools.
Exosomes are rapidly gaining momentum as a strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients. With exosome companies multiplying in number and exosome publications on the rise, it is clear that exosomes will play a crucial role in the cell therapy movement.
Based in Washington, DC, BioInformant is the first and only market research firm to specialize in the stem cell industry. With more than a decade of experience in tracking the stem cell industry (2006 to present), BioInformant has a robust database on which to base future market predictions. Written for companies developing exosome-related products and technologies, the report analyzes strategic opportunities for commercializing products involving exosomes derived from stem cells, as well as other cell sources. [Read more…]
Evox Therapeutics to Collaborate with Boehringer Ingelheim on Exosome-Mediated Drug Delivery
Adds to list of pharmaceutical partners collaborating with Evox
OXFORD, England, December 19, 2017–Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has entered into a research collaboration with Boehringer Ingelheim to investigate exosome-mediated delivery of RNAs with high medical relevance to targets for specific disease areas of focus to Boehringer Ingelheim. The collaboration is part of Boehringer Ingelheim’s Research Beyond Borders (RBB) initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.
[Read more…]
Exosome Diagnostics May Predict Which Cancers are Invasive (and Which are “Safe”)
During the fall months of cancer campaigning, perhaps the biggest awareness remains in shadow: it is not yet possible to prevent patients from receiving needless treatment. As it stands, conservative estimates have determined that greater than 50% of men and women undergo unnecessary surgery and chemotherapy[1]. Many cancers do not deserve the dreaded name and are beginning to be labeled as non-progressive or indolent (“IDLEs”)[2] –a categorization that by itself may prevent untold psychological and physical trauma.
Exosome Diagnostics May Predict Invasiveness
Savvy researchers recognize that the most accurate information providing that distinction will come from what cells release into the blood like molecular mail[3]. Cancer or IDLEs, regardless of threat level, release clues regarding structural rearrangements, as well as tell-tail enzymes that allow cell migration, commandeer local metabolism, and resist their pollution. Profiling these clues would enable scientists and doctors to determine the necessity and precision of therapy, rather than automatically prescribing aggressive treatment.
Studying Exosomes Can Identify Cancer Severity
Such mail is not released “naked” but in little parcels of cell membrane called extracellular vesicles (EVs) or exosomes. Exosomes are produced by all cells in day to day bodily functions, but on a cell-for-cell basis, cancers release larger quantities of exosomes[4]. [Read more…]
Opening Cancer’s Mail: Cancer Exosomes Contain “Inventory of Intent”
Currently over 50% of men and women are directed to unnecessary treatment or surgery. A new approach may help. Professor Alan Doucette of Dalhousie University and his colleagues have published a study funded by the Breast Cancer Society of Canada in which they capture particles released by rapidly growing cells called exosomes. Like parcels containing tools and instructions, exosomes contain an “inventory of intent.” Meaning, the cells that have released them contain genetic material proteins and metabolites that promote invasion of normal cells and commandeer their resources. [Read more…]
